CR20210342A - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
CR20210342A
CR20210342A CR20210342A CR20210342A CR20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A CR 20210342 A CR20210342 A CR 20210342A
Authority
CR
Costa Rica
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
thrombotic
Prior art date
Application number
CR20210342A
Other languages
English (en)
Spanish (es)
Inventor
Martina Schäfer
Pascal Ellerbrock
Kersten Matthias Gericke
Stefan Heitmeier
Adrian Tersteegen
Xianghai Meng
Alexander Hillisch
Katharina Meier
Jan Stampfuss
Hongping Wang
Zengqiang Zou
Sonja Anlauf
Susanne Röhrig
Sebastian Essig
Thomas Neubauer
Dieter Lang
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CR20210342A publication Critical patent/CR20210342A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR20210342A 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos CR20210342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (fr) 2018-12-21 2019-12-18 Dérivés d'oxopyridine substitués

Publications (1)

Publication Number Publication Date
CR20210342A true CR20210342A (es) 2021-08-09

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210342A CR20210342A (es) 2018-12-21 2019-12-18 Derivados de oxopiridina sustituidos

Country Status (22)

Country Link
EP (1) EP3898633A1 (fr)
JP (1) JP2022514303A (fr)
KR (1) KR20210106504A (fr)
CN (1) CN113474348A (fr)
AR (1) AR117435A1 (fr)
AU (1) AU2019407909B2 (fr)
BR (1) BR112021009435A2 (fr)
CA (1) CA3124220A1 (fr)
CL (1) CL2021001613A1 (fr)
CO (1) CO2021007908A2 (fr)
CR (1) CR20210342A (fr)
DO (1) DOP2021000128A (fr)
EA (1) EA202191764A1 (fr)
EC (1) ECSP21043895A (fr)
IL (1) IL283990A (fr)
JO (1) JOP20210161A1 (fr)
MA (1) MA54521A (fr)
MX (1) MX2021007508A (fr)
PE (1) PE20211790A1 (fr)
SG (1) SG11202104384PA (fr)
TW (1) TW202039510A (fr)
WO (1) WO2020127504A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093733A1 (fr) * 2018-03-15 2019-09-19 Bayer Aktiengesellschaft Procede de preparation de deux derives de 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
US20240174633A1 (en) 2021-03-09 2024-05-30 Bayer Aktiengesellschaft Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
JP2024508970A (ja) 2021-03-09 2024-02-28 バイエル・アクチエンゲゼルシヤフト （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形
WO2022189280A1 (fr) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
EP2091947A2 (fr) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Activateurs de glucokinase
EP2978425B1 (fr) 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Inhibiteurs du facteur xia
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2015011087A1 (fr) 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Dérivés de l'oxopyridine substitués et utilisation desdits dérivés comme facteur xia/plasma
CA2928867A1 (fr) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Derives d'oxopyridine substituee
US20170298052A1 (en) 2014-09-24 2017-10-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10071995B2 (en) 2014-09-24 2018-09-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
WO2016046158A1 (fr) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine substitués
WO2016046157A1 (fr) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Dérivés de pyridobenzazépine et de pyridobenzazocine inhibant le facteur xia
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2722425T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas
EP3271332A1 (fr) * 2015-03-19 2018-01-24 Bayer Pharma Aktiengesellschaft Dérivés d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
US20180250280A1 (en) 2015-09-04 2018-09-06 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
MA54521A (fr) 2022-03-30
MX2021007508A (es) 2021-08-05
EP3898633A1 (fr) 2021-10-27
SG11202104384PA (en) 2021-05-28
TW202039510A (zh) 2020-11-01
JP2022514303A (ja) 2022-02-10
WO2020127504A1 (fr) 2020-06-25
CN113474348A (zh) 2021-10-01
AU2019407909B2 (en) 2023-05-25
JOP20210161A1 (ar) 2023-01-30
AU2019407909A1 (en) 2021-05-27
BR112021009435A2 (pt) 2021-08-17
EA202191764A1 (ru) 2021-10-22
AR117435A1 (es) 2021-08-04
DOP2021000128A (es) 2021-09-30
CL2021001613A1 (es) 2021-12-03
KR20210106504A (ko) 2021-08-30
CO2021007908A2 (es) 2021-07-19
CA3124220A1 (fr) 2020-06-25
ECSP21043895A (es) 2021-07-30
PE20211790A1 (es) 2021-09-09
IL283990A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MX2021007508A (es) Derivados de oxopiridina sustituidos.
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12020551973A1 (en) Substituted dihydropyrazolo pyrazine carboxamide derivatives
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PH12016502015A1 (en) Anti-factor d antibody variants and uses thereof
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
WO2016046156A8 (fr) Dérivés d'oxopyridine substitués
WO2018042438A3 (fr) Produits dérivés du sang humain à activité fibrinolytique réduite et leurs utilisations dans des troubles hémostatiques
WO2019040106A3 (fr) Composés, sels associés et méthodes pour le traitement de maladies
PH12021550872A1 (en) Therapeutic compounds
MY150931A (en) Substituted oxazolidinones and their use
JOP20170113B1 (ar) مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2021004860A (es) Piridazinas novedosas.
WO2015165933A3 (fr) Imidazo[1,2-a]pyridine-carboxamides substitués en 6 et leur utilisation
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2019012153A (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso.
TN2015000523A1 (en) Substituted benzoxazoles
ECSP24024658A (es) Derivados de s-alaninato sustituidos
AU2016224843A8 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders